Use of gp130 activators in diabetic neuropathy
AssigneeMerck Serono SA
InventorsMichel Dreano, Pierre-Alain Vitte
Life of this patent
Estimating the term…
Abstract
The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.
Claims15
A method for treating diabetic neuropathy, comprising causing an effective amount of a substance signaling through gp130 to enter the system of a patient in need thereof, wherein said substance
- a) comprises interleukin-6 (IL-6);
- b) is a fragment of a) which binds to gp80 and initiates signaling through gp130;
- c) is a variant of a) which has at least 90% sequence identity with a) and which initiates signaling through gp130;
- or
- d) is a salt, fused protein or functional derivative of a), b), or c) which initiates signaling through gp130.
A method for treating diabetic neuropathy, comprising causing an effective amount of a substance signaling through gp130 to enter the system of a patient in need thereof, wherein said substance is:
- a) interleukin-6 (IL-6);
- b) a fragment of a) which binds to gp80 and initiates signaling through gp130;
- c) a variant of a) which has at least 90% sequence identity with a) and which initiates signaling through gp130,
- or a variant of a N-terminal truncation fragment of a) which binds to gp80 and initiates signaling through gp130, said fragment differing from a) solely by deletion of one or more consecutive amino acid residues from the N-terminal of a), said variant having at least 90% sequence identity with said N-terminal truncation fragment and said variant initiating signaling through gp130;
- d) a fused protein comprising a), b), or c), that initiates signaling through gp130,
- e) a salt or functional derivative of a), b), c) or d), which initiates signaling through gp130.
A method for treating diabetic neuropathy, comprising causing an effective amount of a substance signaling through gp130 to enter the system of a patient in need thereof, wherein said substance is:
- a) interleukin-6 (IL-6);
- b) a fragment of a) which binds to gp80 and initiates signaling through gp130;
- c) a variant of a) which has at least 90% sequence identity with a) and which initiates signaling through gp130,
- d) a fused protein comprising a), b) or c), that initiates signaling through gp130, or
- e) a salt or functional derivative of a), b), c), or d), which initiates signaling through gp130.
Dependencies are inferred from the claim text.